Dementia Support Line
Study to evaluate XBD173 in patients with Alzheimer's disease
Status
Contact
Use the information below to reference this clinical trial when speaking with your healthcare professional or research team.
Note: the information presented on the Clinical Trial Finder is for information only. To join a clinical trial you must meet the eligibility criteria set by the study and the research team will discuss this with you.
Trial description
This study is looking at a medicine called XBD173. We want to find out if it can improve blood flow in the brains of people living with Alzheimer’s disease.
XBD173 works by attaching to a protein called TSPO. TSPO is found in mitochondria, which are tiny parts of our cells that help produce energy. By attaching to TSPO, XBD173 may help the small blood vessels in the brain work better. Better blood flow may help keep the brain healthy and protect it from damage.
If you take part, you will be asked to take XBD173 capsules by mouth. Most participants will take one capsule twice a day for 4 weeks. During another part of the study, participants will take a placebo, which looks the same as XBD173 but does not contain any active medicine.
Most participants will:
- Take either XBD173 or placebo for 4 weeks
- Have a 6-week break
- Then take the other treatment for 4 weeks
Neither you nor the study team will know which treatment you are taking at the time. Find more information about why studies use blinding, randomisation and placebo controls.
Before joining the study, you will attend a screening visit to check whether the study is suitable for you.
During the study, participants will attend 4 main study visits and 2 shorter safety visits. At the main visits, you will have:
- Simple tests of memory and thinking
- A blood sample taken
- An MRI scan of the brain
An MRI scan uses a strong magnet to produce detailed pictures of the brain. It does not use X-rays. Some MRI scans will use a small amount of contrast dye to help show the brain’s blood vessels more clearly. During one MRI scan, you will be asked to breathe air containing a small amount of extra carbon dioxide for a few minutes. This is a safe way to measure how well the brain’s blood vessels respond to changes in blood flow.
The main part of the study lasts about 14 weeks.
XBD173 may not provide a direct benefit to you. However, the information collected may help researchers learn more about Alzheimer’s disease and develop treatments for people in the future. XBD173 has been used safely in previous studies.
We are also inviting healthy volunteers to take part. Healthy volunteers will attend for one MRI scan only and will not receive any study medication. Their results will help researchers compare brain blood flow between people with and without Alzheimer’s disease.
Eligibility criteria
People may be able to take part if they:
- Are aged 60 to 90 years.
- Have a confirmed diagnosis of Alzheimer’s disease, or mild cognitive impairment caused by Alzheimer’s.
- Are able to have an MRI scan. For example, no pacemaker or certain metal in the body, and not too anxious in small spaces.
People may not be able to take part if they:
- Get migraines more than once a month.
The study team will check full eligibility with each person.
Clinical trial team
Age range
Recruitment start
Recruitment end
Disease type
Mechanism of action
Trial locations
Length of participation
Eligibility criteria
People may be able to take part if they:
- Are aged 60 to 90 years.
- Have a confirmed diagnosis of Alzheimer’s disease, or mild cognitive impairment caused by Alzheimer’s.
- Are able to have an MRI scan. For example, no pacemaker or certain metal in the body, and not too anxious in small spaces.
People may not be able to take part if they:
- Get migraines more than once a month.
The study team will check full eligibility with each person.